Cardiac-specific deletion of Mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth

Circulation Research

Volumn 104, Issue 7, 2009, Pages 905-914

  Liu, Wei ^a   Zi, Min ^a   Jin, Jiawei ^a   Prehar, Sukhpal ^a   Oceandy, Delvac ^a   Kimura, Tomomi E ^a   Lei, Ming ^a   Neyses, Ludwig ^a   Weston, Arthur H ^a   Cartwright, Elizabeth J ^a   Wang, Xin ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiac hypertrophy; Genetically modified mice; Signal transduction

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; TRANSCRIPTION FACTOR NFAT; ISOPRENALINE; MAP2K4 PROTEIN, HUMAN; MAP2K4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE DELETION; HEART; HEART DEVELOPMENT; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; MALE; MOUSE; NEWBORN; NONHUMAN; PHYSIOLOGY; PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; SWIMMING; UPREGULATION; ADAPTATION; ANIMAL; BLOOD PRESSURE; CARDIOMEGALY; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEART MUSCLE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TIME;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; APOPTOSIS; BLOOD PRESSURE; CARDIOMEGALY; DISEASE MODELS, ANIMAL; HEART; HEART FAILURE; ISOPROTERENOL; MALE; MAP KINASE KINASE 4; MICE; MICE, KNOCKOUT; MYOCARDIUM; NFATC TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION; SWIMMING; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 65249111703     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.188292     Document Type: Article

References (37)

1. Walsh K. Akt signaling and growth of the heart. Circulation. 2006;113: 2032-2034.
2. Wakatsuki T, Schlessinger J, Elson EL. The biochemical response of the heart to hypertension and exercise. Trends Biochem Sci. 2004;29: 609-617.
3. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239-252.
4. Johnson G, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298: 1911-1912.
5. Flesch M, Margulies KB, Mochmann HC, Engel D, Sivasubramanian N, Mann DL. Differential regulation of mitogen-activated protein kinase in the failing human heart in response to mechanical unloading. Circulation. 2001;104:2273-2276.
6. Cook SA, Sugden PH, Clerk A. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol. 1999;31: 1429-1434.
7. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation. 2007;116:1413-1423.
8. Liang Q, Bueno OF, Wilkins BJ, Kuan CY, Xia Y, Molkentin JD. C-Jun N-terminal kinase (JNK) antagonizes cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J. 2003;22:5079-5089.
9. Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, Parsons S, Braunwart J, Glascock BJ, Klevisky R, Kimball TF, Hewett TE, Molkentin JD. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest. 2003;111:1475-1486.
10. Nishida K, Yamaguchi O, Hirotani S, Hikoso S, Higuchi Y, Watanabe T, Takeda T, Osuka S, Morita T, Kondoh G, Uno Y, Kashiwase K, Taniike M, Nakai A, Matsumura Y, Miyazaki J, Sudo T, Hongo K, Kusakari Y, Kurihara S, Chien KR, Takeda J, Hori M, Otsu K. p38 mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol Cell Biol. 2004;24:10611-10620.
11. Taniike M, Yamaguchi O, Tsujimoto I, Hikoso S, Takeda T, Nakai A, Omiya S, Mizote I, Nakano Y, Higuchi Y, Matsumura Y, Nishida K, Ichijo H, Hori M, Otsu K. Apoptosis signal-regulating kinase 1/p38 signaling pathway negatively regulates physiological hypertrophy. Circulation. 2008;117: 545-552.
12. Wang X, Destrument A, Tournier C. Molecular regulation and physiological roles of MKK4 and MKK7: Insight from animal models. Biochim Biophys Acta. 2007;1773:1349-1357.
13. Fleming Y, Armstrong CG, Morrice N, Paterson A, Goedert M, Cohen P. Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK/JNK) isoforms by mitogen-activated protein kinase kinase 4 MKK4 and MKK7. Biochem J. 2000;352:145-154.
14. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, Takeshita T, Flavell RA, Davis RJ. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003;17:1969-1978.
15. Wang X, Nadarajah B, Robinson AC, McColl BW, Jin JW, Dajas-Bailador F, Boot-Handford RP, Tournier C. Targeted deletion of the mitogen-activated protein kinase kinase 4 gene in the nervous system causes severe brain developmental defects and premature death. Mol Cell Biol. 2007;27:7935-7946.
16. Choukroun G, Hajjar R, Kyriakis JM, Bonventre JV, Rosenzweig A, Force T. Role of the stress-activated protein kinase in endothelin-induced cardiomyocyte hypertrophy. J Clin Invest. 1998;102:1311-1320.
17. Choukroun G, Hajjar R, Fry S, De Monte F, Haq S, Guerrero JL, Picard M, Rosenzweig A, Force T. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinase/c-Jun NH(2)-terminal kinase. J Clin Invest. 1999;104:391-398.
18. Sadoshima J, Montagne O, Wang Q, Yang G, Warden J, Liu J, Takagi G, Karoor V, Hong C, Johnson GL, Vatner DE, Vatner SF. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest. 2002;110:271-279.
19. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, Wang Z, kerber RE, Weiss RM. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation. 2000;101: 2863-2869.
20. DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Courtois M, Muslin AJ. Akt1 is required for physiological cardiac growth. Circulation. 2006;113:2097-2104.
21. Ruwhof C, van der Laarse A. Mechanical stress-induced cardiac hyper-trophy: Mechanisms and signal transduction pathways. Cardiovasc Res. 2000;47:23-37.
22. Lips DJ, de Windt LJ, van Kraaij DJW, Doevendans PA. Molecular determinants of myocardial hypertrophy and failure: Alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J. 2003;24: 883-896.
23. Molkentin D. Calcineurin-NFAT signalling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res. 2004; 63:467-475.
24. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olsen EN, Basssel-Duby R, Williams RS. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res. 2000;87:E61-e68.
25. Frank D, Kuhn C, van Eickels M, Gehring D, Hanselmann C, Lippl S, Will R, Katus HA, Frey N. Calsarcin-1 protects against Angiotensin-IIinduced cardiac hypertrophy. Circulation. 2007;116:2587-2596.
26. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res. 2004; 94:110-118.
27. De Windt LJ, Lim HW, Haq S, Force T, Molkentin JD. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. J Biol Chem. 2000;275:13571-13579.
28. Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med. 2009; 15:75-83.
29. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. Activation MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 2001;20:2757-2767.
30. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, Izumo S. AKT/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol. 2002;22:2799-2809.
31. Hardt SE, Sadoshima J. Glycogen synthase kinase-3a novel regulator of cardiac hypertrophy and development. Circ Res. 2002;90:1055-1063.
32. Hilfiker-Kleiner D, Hilfiker A, Kaminski K, Schaefer A, Park JK, Michel K, Quint A, Yaniv M, Weitzman JB, Drexler H. Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart. Circulation. 2005;112:1470-1477.
33. Aoki H, Kang PM, Hampe J, Yoshimura K, Noma T, Matsuzaki M, Izumo S. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult myocytes. J Biol Chem. 2002;277: 10244-10250.
34. Andrek P, Zang J, Dougherty C, Slepak TI, Webster KA, Bishopric NH. Cytoprotection by Jun kinase during nitric oxide-induced cardiac myocyte apoptosis. Circ Res. 2001;88:305-312.
35. Ichijo H, Nishida E, Irie K, Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 1997;275:90-94.
36. Petrich BG, Eloff BC, Lerner DL, Kovacs A, Saffitz JE, Rosenbaum DS, Wang Y. Targeted activated of c-Jun N-terminal kinase in vivo induces restrictive cardiomyopathy and conduction defects. J Biol Chem. 2004; 279:15330-15338.
37. Petrich BG, Gong X, Lerner DL, Wang X, Brown JH, Saffitz JE, Wang Y. c-Jun N-terminal kinase activation mediates downregulation of connexin 43 in cardiomyocytes. Circ Res. 2002;91:640-647.